.png)
The journey through IVF is complex, demanding precision, coordination, and compassion at every step for clinics. At MedITEX IVF, we empower fertility clinics worldwide with intelligent software that simplifies and optimizes this process. Developed by reproductive medicine and IT experts, our platform supports clinics in managing all aspects of assisted reproduction — from spermiograms and oocyte analyses to treatment planning, documentation, and quality management.
Used in nearly all fertility clinics across Germany and many more worldwide, MedITEX IVF is also an official partner and data carrier of the German and Hungarian IVF registries, ensuring the highest standards of data integrity, accuracy, and compliance. With more than 20 years of experience and continuous development, MedITEX has become a trusted foundation for both clinical excellence and reliable data management.
But our impact extends beyond the day-to-day operations of fertility clinics. The structured, high-quality data collected through MedITEX is also contributing to scientific progress, powering research that helps understand and improve fertility treatments worldwide.
In this article, we’re proud to highlight how MedITEX IVF is being used in clinical studies over the recent years, providing researchers with decades of reliable data and helping to generate new insights into reproductive medicine and ART:
1. The OPERA Project – Large-Scale Real-World ART Data
The OPERA project is a major European multicentre initiative that demonstrates the power of real-world data (RWD) in assisted reproductive technology (ART). It collected over 95,000 ART cycles from 18 clinics across Germany and Italy (2016–2020) to explore how patient-level real-world evidence can improve fertility care.
Two Key Analyses Using MedITEX IVF
1.1 Feasibility of Multinational RWD Collection (Fusi et al. (2023))
- Focus: Could comprehensive patient-level ART data be reliably collected across multiple countries?
- Result: Over 75,000 cycles were analyzed, confirming feasibility and high data quality.
- MedITEX Role: Standardized and anonymized patient and treatment data, enabling secure transfer to the central study database.
1.2 Detailed ART Outcomes and Trends (Francavilla et al. (2025))
- Focus: What insights can be drawn from routine ART practice regarding stimulation protocols, fertilization rates, and pregnancy outcomes?
- Result: Analysis of 95,000 cycles showed real-world ART is effective and safe, with low complication rates.
- MedITEX Role: Collected and standardized all patient and treatment data across centers, ensuring consistent, high-quality data for large-scale analysis.
2. Embryo Development and Hormonal Influence (Baldini et al., 2024)
- Focus: Investigated how a premature rise in progesterone (≥ 1.5 ng/ml) on the day of hCG trigger affects embryo development in ICSI cycles.
- Result: Higher progesterone levels were associated with more retrieved and mature oocytes, more blastocysts, and faster early embryo development, without negatively impacting embryo quality.
- MedITEX Role: Enabled precise patient matching for the control group based on clinical and demographic factors, ensuring balanced groups and reliable data analysis.
3. Fertility Preservation via Ovarian Tissue Cryopreservation (Emrich et al., 2025)
- Focus: Analyzed over 2,400 cases of ovarian tissue cryopreservation (OTC) to understand long-term storage outcomes in children, adolescents, and adults.
- Result: Younger patients stored tissue longer; sarcomas and hematologic malignancies were the main indications; ovarian tissue transplantation (OTT) showed promising pregnancy and birth rates.
- MedITEX Role: Managed and analyzed patient data spanning two decades, ensuring consistent documentation, traceability, and reliable long-term analysis.
4. Evaluating a New Sperm Preparation Technique (Baldini et al., 2020)
- Focus: Compared a novel horizontal sperm migration method to the traditional swim-up technique in over 1,000 ICSI cycles.
- Result: Cleavage and blastocyst rates were higher with the new method, improving sperm quality and embryo development, along with time and cost savings.
- MedITEX Role: Anonymized, managed, and stored patient and treatment data for over 1,000 cycles, supporting robust analysis and randomization.
5. BMI and IVF Outcomes in Endometriosis Patients (Garalejic et al., 2017)
- Focus: Explored whether BMI affects IVF success in non-obese women with endometriosis.
- Result: Slightly higher BMI within the non-obese range did not negatively affect IVF outcomes, contrary to trends in the general infertile population.
- MedITEX Role: Provided consistent electronic patient data collection, management, and validation across years, enabling high-quality retrospective analysis.
6. Ovarian Tissue Cryopreservation Outcomes (John et al., 2023)
- Focus: Examined long-term outcomes of women storing ovarian tissue between 2000 and 2021.
- Result: On average, patients stored tissue for five years, and about 50% conceived naturally without using the frozen tissue. The study highlights the importance of OTC for fertility preservation.
- MedITEX Role: Digitized and analyzed historic patient and storage data spanning more than two decades. Its secure, reliable architecture ensured accurate, traceable, and compliant data for large-scale retrospective research.
The use of MedITEX IVF in these studies shows that our software is more than a digital tool, it’s a bridge between everyday clinical practice and scientific discovery. By providing secure, structured, and high-quality data, MedITEX helps researchers uncover new insights that ultimately improve fertility treatments and patient outcomes worldwide.
We’re proud that clinics and scientists alike trust MedITEX to power progress in reproductive medicine and we look forward to continuing to support both innovation and life itself.
